Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11,047 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A luminal non-coding RNA-based genomic classifier confirms favourable outcomes in patients with clinically organ-confined bladder cancer treated with radical cystectomy.
de Jong JJ, Proudfoot JA, Daneshmand S, Svatek RS, Naryan V, Gibb EA, Davicioni E, Joshi S, Dahmen A, Li R, Inman BA, Shah P, Chaplin I, Wright J, Lotan Y. de Jong JJ, et al. Among authors: wright j. BJU Int. 2024 Nov 1. doi: 10.1111/bju.16572. Online ahead of print. BJU Int. 2024. PMID: 39485082
Molecular Characterization of Neuroendocrine-like Bladder Cancer.
Batista da Costa J, Gibb EA, Bivalacqua TJ, Liu Y, Oo HZ, Miyamoto DT, Alshalalfa M, Davicioni E, Wright J, Dall'Era MA, Douglas J, Boormans JL, Van der Heijden MS, Wu CL, van Rhijn BWG, Gupta S, Grivas P, Mouw KW, Murugan P, Fazli L, Ra S, Konety BR, Seiler R, Daneshmand S, Mian OY, Efstathiou JA, Lotan Y, Black PC. Batista da Costa J, et al. Among authors: wright j. Clin Cancer Res. 2019 Jul 1;25(13):3908-3920. doi: 10.1158/1078-0432.CCR-18-3558. Epub 2019 Apr 5. Clin Cancer Res. 2019. PMID: 30952638
Long non-coding RNAs identify a subset of luminal muscle-invasive bladder cancer patients with favorable prognosis.
de Jong JJ, Liu Y, Robertson AG, Seiler R, Groeneveld CS, van der Heijden MS, Wright JL, Douglas J, Dall'Era M, Crabb SJ, van Rhijn BWG, van Kessel KEM, Davicioni E, Castro MAA, Lotan Y, Zwarthoff EC, Black PC, Boormans JL, Gibb EA. de Jong JJ, et al. Among authors: wright jl. Genome Med. 2019 Oct 17;11(1):60. doi: 10.1186/s13073-019-0669-z. Genome Med. 2019. PMID: 31619281 Free PMC article.
Validation of a neuroendocrine-like classifier confirms poor outcomes in patients with bladder cancer treated with cisplatin-based neoadjuvant chemotherapy.
Grivas P, Bismar TA, Alva AS, Huang HC, Liu Y, Seiler R, Alimohamed N, Cheng L, Hyndman ME, Dabbas B, Black PC, Davicioni E, Wright JL, Ornstein MC, Mian OY, Kaimakliotis HZ, Gibb EA, Lotan Y. Grivas P, et al. Urol Oncol. 2020 Apr;38(4):262-268. doi: 10.1016/j.urolonc.2019.11.004. Epub 2019 Dec 4. Urol Oncol. 2020. PMID: 31812633
Distribution of Molecular Subtypes in Muscle-invasive Bladder Cancer Is Driven by Sex-specific Differences.
de Jong JJ, Boormans JL, van Rhijn BWG, Seiler R, Boorjian SA, Konety B, Bivalacqua TJ, Wheeler T, Svatek RS, Douglas J, Wright J, Dall'Era M, Crabb SJ, Efstathiou JA, van der Heijden MS, Mouw KW, Miyamoto DT, Lotan Y, Black PC, Gibb EA, Porten SP. de Jong JJ, et al. Among authors: wright j. Eur Urol Oncol. 2020 Aug;3(4):420-423. doi: 10.1016/j.euo.2020.02.010. Epub 2020 Mar 20. Eur Urol Oncol. 2020. PMID: 32205136
Comparative effectiveness of neoadjuvant chemotherapy in bladder and upper urinary tract urothelial carcinoma.
D'Andrea D, Matin S, Black PC, Petros FG, Zargar H, Dinney CP, Cookson MS, Kassouf W, Dall'Era MA, McGrath JS, Wright JL, Thorpe AC, Morgan TM, Holzbeierlein JM, Bivalacqua TJ, Sridhar SS, North S, Barocas DA, Lotan Y, Stephenson AJ, van Rhijn BW, Spiess PE, Daneshmand S, Shariat SF. D'Andrea D, et al. Among authors: wright jl. BJU Int. 2021 May;127(5):528-537. doi: 10.1111/bju.15253. Epub 2020 Oct 14. BJU Int. 2021. PMID: 32981193 Free PMC article.
Neoadjuvant chemotherapy plus radical cystectomy versus radical cystectomy alone in clinical T2 bladder cancer without hydronephrosis.
Soria F, Black PC, Fairey AS, Cookson MS, Yu EY, Kassouf W, Dall'Era MA, Sridhar SS, McGrath JS, Wright JL, Thorpe AC, Morgan TM, Daneshmand S, Holzbeierlein JM, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Grivas P, Stephenson AJ, Shah JB, van Rhijn BW, Spiess PE, Shariat SF, Gontero P. Soria F, et al. Among authors: wright jl. BJU Int. 2021 Jul;128(1):79-87. doi: 10.1111/bju.15289. Epub 2020 Nov 21. BJU Int. 2021. PMID: 33152179 Free article.
Molecular Characterization of Residual Bladder Cancer after Neoadjuvant Pembrolizumab.
Necchi A, de Jong JJ, Raggi D, Briganti A, Marandino L, Gallina A, Bandini M, Dabbas B, Davicioni E, Capitanio U, Montorsi F, Seiler R, Wright JL, Lotan Y, Black PC, Gibb EA. Necchi A, et al. Among authors: wright jl. Eur Urol. 2021 Aug;80(2):149-159. doi: 10.1016/j.eururo.2021.03.014. Epub 2021 Mar 28. Eur Urol. 2021. PMID: 33785257
Patients with Muscle-Invasive Bladder Cancer with Nonluminal Subtype Derive Greatest Benefit from Platinum Based Neoadjuvant Chemotherapy.
Lotan Y, de Jong JJ, Liu VYT, Bismar TA, Boorjian SA, Huang HC, Davicioni E, Mian OY, Wright JL, Necchi A, Dall'Era MA, Kaimakliotis HZ, Black PC, Gibb EA, Boormans JL. Lotan Y, et al. Among authors: wright jl. J Urol. 2022 Mar;207(3):541-550. doi: 10.1097/JU.0000000000002261. Epub 2021 Oct 13. J Urol. 2022. PMID: 34643090
Alignment of molecular subtypes across multiple bladder cancer subtyping classifiers.
Reike MJ, de Jong JJ, Bismar TA, Boorjian SA, Mian OY, Wright JL, Dall'Era MA, Kaimakliotis HZ, Lotan Y, Boormans JL, Black PC, Gibb EA. Reike MJ, et al. Among authors: wright jl. Urol Oncol. 2024 Jun;42(6):177.e5-177.e14. doi: 10.1016/j.urolonc.2024.01.027. Epub 2024 Mar 12. Urol Oncol. 2024. PMID: 38480079
11,047 results
You have reached the last available page of results. Please see the User Guide for more information.